These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12620179)

  • 1. Clinical inquiries. Does screening for microalbuminuria in diabetes prevent complications?
    Hale WA; Nashelsky J; Wilson SA
    J Fam Pract; 2003 Mar; 52(3):229-31. PubMed ID: 12620179
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of angiotensin II inhibition or blockade on the progression of chronic renal disease.
    Cantarovich F; Rangoonwala B
    Int J Clin Pract; 2003 Nov; 57(9):801-22. PubMed ID: 14686572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACE inhibitors and antihypertensive treatment in diabetes: focus on microalbuminuria and macrovascular disease.
    Mogensen CE
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):234-9. PubMed ID: 11881030
    [No Abstract]   [Full Text] [Related]  

  • 5. Diabetic nephropathy: common questions.
    Thorp ML
    Am Fam Physician; 2005 Jul; 72(1):96-9. PubMed ID: 16035688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic nephropathy.
    Goto A
    N Engl J Med; 2002 Sep; 347(12):947-8; author reply 947-8. PubMed ID: 12239270
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical practice. Nephropathy in patients with type 2 diabetes.
    Remuzzi G; Schieppati A; Ruggenenti P
    N Engl J Med; 2002 Apr; 346(15):1145-51. PubMed ID: 11948275
    [No Abstract]   [Full Text] [Related]  

  • 8. Should Angiotensin converting enzyme inhibitors be used in children with type 1 diabetes and microalbuminuria?
    Almerie MQ; Williams RM; Acerini CL
    Arch Dis Child; 2008 Jul; 93(7):633-5. PubMed ID: 18285389
    [No Abstract]   [Full Text] [Related]  

  • 9. [Should normotensive diabetic patients with microalbuminuria be treated with angiotensin converting enzyme inhibitors?].
    Feldt-Rasmussen BF
    Ugeskr Laeger; 2002 Apr; 164(14):1907-9. PubMed ID: 11957423
    [No Abstract]   [Full Text] [Related]  

  • 10. Microalbuminuria in diabetes mellitus.
    Tobe SW; McFarlane PA; Naimark DM
    CMAJ; 2002 Sep; 167(5):499-503. PubMed ID: 12240818
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical inquiries. Angiotensin blockade for diabetes: monitor microalbuminuria?
    Muench J; Blenning C; Judkins DZ; Vincent C
    J Fam Pract; 2007 Feb; 56(2):145-6. PubMed ID: 17270123
    [No Abstract]   [Full Text] [Related]  

  • 12. Screening for microalbuminuria.
    Peterson KA
    J Fam Pract; 2001 Aug; 50(8):674-5. PubMed ID: 11509160
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of the patient with diabetes mellitus and risk of nephropathy: what do we know, and what do we need to learn?
    Hollenberg NK
    Arch Intern Med; 2004 Jan; 164(2):125-30. PubMed ID: 14744834
    [No Abstract]   [Full Text] [Related]  

  • 14. ACE inhibitors versus angiotensin receptor blockers in diabetic nephropathy: is there a winner?
    Lewis EJ; Lewis JB
    J Am Soc Nephrol; 2004 May; 15(5):1358-60. PubMed ID: 15100380
    [No Abstract]   [Full Text] [Related]  

  • 15. Slowing progression along the renal disease continuum.
    Kopyt NP
    J Am Osteopath Assoc; 2005 Apr; 105(4):207-15. PubMed ID: 15928338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ramipril and new therapeutic possibilities for ACE-inhibitors].
    Vespasiani Gentilucci U; Picardi A
    Clin Ter; 2000; 151(4):307-8. PubMed ID: 11107682
    [No Abstract]   [Full Text] [Related]  

  • 17. Angiotensin receptor blockers do not have an advantage over angiotensin-converting inhibitors [corrected].
    Harman-Boehm I
    Isr Med Assoc J; 2004 May; 6(5):296-8. PubMed ID: 15151373
    [No Abstract]   [Full Text] [Related]  

  • 18. [Microalbuminuria is an early marker for increased morbidity and mortality].
    Bramlage P; Wittchen HU; Pittrow D; Dikow R; Kirch W; Lehnert H; Ritz E
    Fortschr Med Orig; 2003 Feb; 121 Suppl 1():28-32. PubMed ID: 14732947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early screening for nephropathy initiative.
    Monsaert RP
    Del Med J; 2006 Apr; 78(4):153-4. PubMed ID: 16719144
    [No Abstract]   [Full Text] [Related]  

  • 20. Blood pressure control and nephroprotection in diabetes.
    Abbott K; Basta E; Bakris GL
    J Clin Pharmacol; 2004 Apr; 44(4):431-8. PubMed ID: 15051752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.